Ocular Oncology

Top Story

Regression time shorter with ophthalmic artery chemosurgery plus intravitreous chemotherapy

May 30, 2017

Ophthalmic artery chemosurgery with intravitreous chemotherapy to treat class 3 retinoblastoma vitreous seeds resulted in a shorter time to regression compared with ophthalmic artery chemosurgery alone, according to a retrospective study.

Researchers at Memorial Sloan-Kettering Cancer Center included 40 eyes containing clouds (class 3 vitreous seeds) of 40 retinoblastoma patients; 19 were treated with ophthalmic artery chemosurgery (OAC) and 21 were treated with OAC plus intravitreous and periocular chemotherapy. Time to regression of seeds, ocular survival and disease-free survival were the main outcome measures.

Palladium-103 brachytherapy deemed safe, pupil-sparing treatment

April 17, 2017
Iris melanoma treated with palladium-103 plaque brachytherapy showed patterns of regression that included decreased intrinsic tumor vascularity, increased tumor…

Aura Biosciences’ ocular melanoma treatment receives fast track designation

April 3, 2017
AU-011, an investigational, first-in-class targeted therapy for ocular melanoma treatment, was granted fast track designation by the FDA, according to a press release…
Meeting NewsVideo

VIDEO: Effective therapies needed for uveal melanoma

March 30, 2017
NEW YORK — Some clinical trials evaluating standard melanoma immunotherapies have been disappointing for metastatic uveal melanoma, Alexander Shoushtari, MD,
Original Article

Meta-analysis of the FDA Reports on Patient-Reported Outcomes Using the Three Latest Platforms for LASIK

Journal of Refractive Surgery, June 2017, Volume 33 Issue 6
To analyze the impact of the three latest U.S. Food and Drug Administration (FDA)–approved lasers on patient-reported…
More »
CME

Best of Retina Forum® 2016 - Diabetic Retinopathy: A Revolution in Treatment Options

This activity is supported by educational grants from Carl Zeiss Meditec, Inc. and Regeneron Pharmaceuticals, Inc.

Diabetic retinopathy (DR) is an insidious, progressive disease. Diabetic macular edema (DME), which can occur at any…
More »
Resource Centers
Video

Uveal melanoma treatment improving but metastasis persists

September 30, 2016
More »
In the Journals

Regression time shorter with ophthalmic artery chemosurgery plus intravitreous chemotherapy

May 30, 2017
Ophthalmic artery chemosurgery with intravitreous chemotherapy to treat class 3 retinoblastoma vitreous seeds resulted in a shorter time to…

Palladium-103 brachytherapy deemed safe, pupil-sparing treatment

April 17, 2017
Iris melanoma treated with palladium-103 plaque brachytherapy showed patterns of regression that included decreased intrinsic tumor vascularity…

Aura Biosciences’ ocular melanoma treatment receives fast track designation

April 3, 2017
AU-011, an investigational, first-in-class targeted therapy for ocular melanoma treatment, was granted fast track designation by the FDA, according…

Meeting NewsVideo

VIDEO: Effective therapies needed for uveal melanoma

March 30, 2017
NEW YORK — Some clinical trials evaluating standard melanoma immunotherapies have been disappointing for metastatic uveal melanoma, Alexander

Fine needle aspiration biopsy safe in uveal melanoma

March 21, 2017
A study carried out at Retina Consultants of Houston and Houston Methodist Hospital confirmed the safety of fine needle aspiration biopsy in patients…

Meeting News

Speaker: Consider intraocular tumors before enucleation, evisceration

March 14, 2017
PHILADELPHIA — Imaging studies should be completed before enucleation or evisceration surgeries to rule out unsuspected tumors, a speaker said…

Meeting News

Fewer malignant conjunctival tumors seen in children

March 10, 2017
PHILADELPHIA – Conjunctival tumors in children statistically are more often benign than those in adults and can be differentiated by using a…

FDA News

FDA clears IND application for Aura Biosciences’ AU-011 for ocular melanoma

February 6, 2017
The FDA has cleared an investigational new drug application for light-activated AU-011 in ocular melanoma, allowing clinical testing to begin…

In the Journals

Study: Conjunctival tumors in children rarely malignant

February 3, 2017
In a study of cases spanning nearly 40 years, only 3% of conjunctival tumors in children were malignant. The retrospective case series analyzed the…

In the Journals PlusPerspective

Topotecan-based regimen improves ocular salvage, vision preservation in advanced retinoblastoma

December 2, 2016
The combination of systemic vincristine, topotecan and carboplatin with aggressive focal therapies improved ocular salvage and preserved vision in…

More Headlines »
Advertisement
Advertisement